Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth

Dublin, April 25, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth" report to their offering.

Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia - high blood glucose levels - that results from defects in insulin secretion, insulin action, or a combination of these. This chronic hyperglycemia is associated with long-term damage, dysfunction and failure of multiple organs including the eyes, kidneys, nerves, heart and blood vessels.

The vast majority of diabetes mellitus patients can be classified as having either Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM). Approximately 85-95% of all diabetics have T2DM.

T2DM treatment has been revolutionized in the past decade, especially with the increased use of new therapies. The marketed products landscape comprises a wide range of treatment options, including biguanide (metformin), sulfonylureas, thiazolidinediones, GLP-1 receptor agonist, DPP-4 inhibitor, SGLT-2 inhibitor, and insulin therapies.

Nevertheless, significant unmet need remains for products that can offer better glycemic control as well as the prevention and cure of diabetic complications, such as diabetic nephropathy, retinopathy, and cardiovascular disease.

Scope

The current T2DM in the Asia-Pacific (APAC) market contains novel products, including Jardiance - a SGLT-2 inhibitor; Victoza - a GLP-1 receptor agonist; and Galvus - a DPP-4 inhibitor.

- What are the competitive advantages of the existing novel drugs?
With over 500 active pipeline molecules, most of the late-stage investigational drug candidates are being evaluated, featuring improved dosing regimens and administration routes, in comparison to currently marketed products and combination therapies.
- Which classes of novel drugs are most prominent within the pipeline?
- Is there strong potential for the pipeline to address unmet needs within the T2DM market?
Analysis of clinical trials, since 2006, identified that the failure rates of T2DM molecules were highest in Phase II, at 54%, with the overall attrition rate for T2DM at 82.6%.
- How do failure rates vary by product stage of development, molecule type, and mechanism of action?
- How do other factors, such as average trial duration and trial size influence the costs and risks associated with product development?
Over the 2014-2021 forecast period, the T2DM therapeutics in the APAC markets is expected to increase in value at a CAGR of 7.7%, from $6.07 billion to over $10.2 billion.

Key Topics Covered:

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Disease Overview
2.2 Classification
2.3 Symptoms
2.4 Etiology
2.5 Pathophysiology
2.6 Epidemiology
2.7 Prognosis
2.8 Co-morbidities and Complications
2.9 Diagnosis
2.10 Assessing Treatment Effectiveness
2.11 Treatment
2.11.1 Non-insulin T2DM Therapies
2.11.2 Insulin T2DM Therapies
2.12 Treatment Segments
2.12.1 Non-insulin therapies
2.12.2 Insulin Therapies

3 Marketed Products
3.1 Overview
3.2 Biguanides
3.2.1 Metformin
3.3 Sulfonylureas
3.4 Thiazolidinediones
3.4.1 Pioglitazone
3.5 GLP-1 receptor agonists
3.5.1 Byetta (exenatide)
3.5.2 Bydureon (exenatide)
3.5.3 Victoza (liraglutide)
3.5.4 Lyxumia (lixisenatide)
3.5.5 Tanzeum (albiglutide)
3.5.6 Trulicity (dulaglutide)
3.6 DPP-4 Inhibitors
3.6.1 Januvia/Glactiv (sitagliptin)
3.6.2 Galvus (vildagliptin)
3.6.3 Onglyza (saxagliptin)
3.6.4 Trazenta (linagliptin)
3.6.5 Zafatek (trelagliptin succinate)
3.6.6 Marizev (omarigliptin)
3.7 SGLT-2 Inhibitors
3.7.1 Forxiga (dapagliflozin)
3.7.2 Invokana (canagliflozin)
3.7.3 Jardiance (empagliflozin)
3.8 Insulin Therapies
3.8.1 Lantus (insulin glargine)
3.8.2 Levemir (insulin detemir)
3.8.3 Tresiba (insulin degludec)
3.8.4 Toujeo/ Lantus XR (insulin glargine)
3.9 Marketed Products Heat Maps

4 Pipeline
4.1 Overview
4.2 Pipeline Distribution by Stage of Development, Molecule Type and Program Type
4.3 Pipeline Distribution by Molecular Target
4.4 Clinical Trial Landscape
4.5 Promising Pipeline Molecules
4.5.1 NN-9535 (subcutaneous semaglutide) and OG-217SC (oral semaglutide) - Novo Nordisk
4.5.2 ITCA 650 - Intarcia Therapeutics
4.5.3 Ertugliflozin - Pfizer
4.6 Pipeline Products Heat Map

5 Market Forecast to 2021
5.1 Geographical Markets
5.2 Asia-Pacific Markets
5.3 China
5.4 India
5.5 Australia
5.6 Japan
5.7 Drivers and Barriers for the T2DM Therapeutics Market

6 Strategic Consolidations
6.1 Licensing Deals
6.1.1 AbbVie Collaborates with Halozyme Therapeutics to Bank on its ENHANZE Technology
6.1.2 Janssen Collaborates with Halozyme Therapeutics to Bank on its ENHANZE Technology
6.1.3 Emisphere Signs Licensing Agreement with Novo Nordisk to Develop Oral Formulations Targeting Metabolic Indications
6.1.4 Amunix Announces Exclusive Agreements with Naia to Develop GLP-1 and GLP-2 XTEN Products
6.2 Co-development Deals
6.2.1 Intarcia Therapeutics Enters into Co-Development Agreement with Servier for ITCA 650 (DUROS delivery exenatide)
6.2.2 Merck Enters into Co-Development Agreement with Pfizer for ertugliflozin
6.2.3 AstraZeneca Enters into Research Agreement with Inserm
6.2.4 Intarcia Therapeutics Enters into Co-Development Agreement with Numab
6.2.5 AstraZeneca Enters into Co-development Agreement with Bristol-Myers Squibb

7 Appendix

Companies Mentioned

- AbbVie
- Amunix
- AstraZeneca
- Bristol-Myers Squibb
- Emisphere
- Halozyme Therapeutics
- Intarcia Therapeutics
- Janssen
- Merck
- Naia
- Novo Nordisk
- Numab
- Pfizer

For more information visit http://www.researchandmarkets.com/research/ls9h6f/type_2_diabetes